Abstract PD13-01: PD13-01 Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial
María Vidal(Inserm), Meritxell Bellet Ezquerra, Xavier González(Breast Cancer Research Foundation), Miguel A. Luna, Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Mireia Margelí Vila(Institut Català d'Oncologia), Fernando Salvador(Solti), Patricia Galván(Vall d'Hebron Institute of Oncology), Alejandra Espinosa, Esther Sanfeliu(Hospital Clínic de Barcelona), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Kepa Amillano(Hospital Universitari Sant Joan de Reus), Isaac Cerbrecos(Hospital Clínic de Barcelona), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Aleix Prat(Hospital Clínic de Barcelona), Tomás Cortadellas(Universitat Autònoma de Barcelona), Christian Siso(Breast Cancer Research Foundation), Claudette Falato(Karolinska Institutet)
Cited by 12
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k